Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

beta-thalassemia

- PMLiVE

Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

The rare inherited disease affects approximately 11,000 people in the UK

- PMLiVE

Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval

The rare inherited disease affects more than 109,000 people worldwide

- PMLiVE

Vertex’s triple combination cystic fibrosis therapy Alyftrek approved by MHRA

Over 11,000 people in the UK are affected by the rare genetic disease

- PMLiVE

NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease

About 15,000 people in England are living with the inherited blood disorder

- PMLiVE

NICE recommends Vertex/CRISPR’s Casgevy gene therapy for beta thalassaemia

An estimated 460 patients in England with severe cases of the blood disorder could be eligible for Casgevy

- PMLiVE

Novo Nordisk receives CHMP recommendation for Wegovy cardiovascular label update

The weight management drug was found to significantly reduce the risk of major adverse cardiovascular events

- PMLiVE

Astellas’ zolbetuximab combination receives positive CHMP opinion for advanced gastric cancer

Gastric cancer is currently the sixth-most common cause of cancer-related mortality in Europe

- PMLiVE

GSK’s RSV vaccine Arexvy recommended by CHMP for adults aged 50 to 59 years

The positive opinion comes just over a year after Arexvy was approved for those aged 60 and over

- PMLiVE

Boehringer Ingelheim’s Spevigo recommended by CHMP for generalised pustular psoriasis

The chronic neutrophilic inflammatory disease can lead to severe complications, including multisystem organ failure

- PMLiVE

Merck and Astellas/Pfizer’s bladder cancer combination receives positive CHMP opinion

More than 165,000 new cases of bladder cancer are diagnosed in the EU every year

- PMLiVE

LEO Pharma receives CHMP recommendation for Anzupgo in chronic hand eczema

About 70% of patients with severe cases of the skin condition report problems performing everyday activities

- PMLiVE

Johnson & Johnson’s Yuvanci recommended by CHMP to treat pulmonary arterial hypertension

The rare form of pulmonary hypertension affects around 30,000 people in the EU

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links